Compare Medpace Holdings Inc (MEDP) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.

The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.

Dentsply Sirona (XRAY) trades at $13.65, down 2.91% on the day, with a mixed technical picture showing a bullish moving average signal but overbought RSI levels. Fundamentally, the company reported a net loss of $598 million for 2025, with negative profit margins and an elevated EV/EBITDA of 91.48, though revenue remains stable near $3.7 billion. Recent news includes the appointment of a new CFO and expanded U.S. distribution partnerships, while the upcoming Q2 2026 earnings call on August 6 is a key near-term catalyst.

The outlook remains challenging due to persistent losses and margin pressure, offset by strategic growth initiatives. Investment opportunities lie in the company's market leadership and digital dentistry expansion, but risks include high debt levels, competitive pressures, and the need for a successful turnaround. Analyst consensus is Hold with a price target of $13.33, indicating limited near-term upside from current levels.